NRx Pharmaceuticals Stock Rating Reiterated at Buy by H.C. Wainwright

H.C. Wainwright has reiterated its 'buy' rating on NRx Pharmaceuticals. No specific price target or P/E ratio were mentioned in the announcement. The firm's endorsement suggests confidence in NRx's future performance, which could influence investor sentiment positively. Maintaining a 'buy' recommendation is significant as it may encourage potential investors to consider NRx Pharmaceuticals (NRXP) for their portfolios.